Health Equity



dr gordon pulmonologist :: Article Creator

Division Of Pediatric Pulmonology

The Division of Pediatric Pulmonology was started by Dr. Gunyon M. Harrison at Texas Institute of Rehabilitation and Research and Texas Children's Hospital in the 1950's.

Dr. Harrison is well known for his interest in polio and care of patients with respiratory muscle disease. In 1960, the Cystic Fibrosis Foundation began to create regional CF centers and selected Baylor College of Medicine as its first recipient of CFF grant for a CF center and named Dr. Harrison as its first medical director. In 1977, Dr. Harrison recommended hiring a young, career driven and dedicated physician, who he had trained and worked with for many years, Dr. Dan K. Seilheimer. Among his activities at TIRR,

Dr. Seilheimer served as co-director of the respiratory therapy program, directing the pulmonary function laboratory and working with Dr. Harrison in training pediatric residents and pediatric pulmonary fellows concerning patient management in the respiratory center. Dr. Seilheimer was involved in the development and growth of Texas Children's Respiratory Care Department and in the accreditation of the Cystic Fibrosis Care Center at Baylor College of Medicine and Texas Children's Hospital. In 1984, he was appointed Section Head of the Pulmonary Medicine Service at Texas Children's Hospital. Dr. Seilheimer was awarded the Lay Education Award from the American Academy of Pediatrics for his leadership developing The CF Family Education Program. This award-winning comprehensive self-management for patients and families is still in use nationally today.

Through the years, Dr. Seilheimer's dedication and commitment to the care of respiratory patients and their families allowed for the expansion of services and treatment offered to them. Among the physicians that joined the medical staff were Dr. Leland L. Fan and Dr. George B. Mallory, Jr. Both of these physicians brought their knowledge and expertise to the section in the area of pediatric interstitial lung disease and pediatric lung transplantation, respectively.

After 25 years of serving the Pediatric Pulmonary Section, Dr. Seilheimer retired in 2009 and handed over the reins to Dr. Peter W. Hiatt. Dr. Hiatt has continued to expand the services of the section and under his direction, the Sleep Medicine Program and the Pulmonary Hypertension Services have grown. We also now offer Aerodigestive, Life-Threatening Asthma, Pulmonary Sickle Cell, Ventilator and Muscular Dystrophy Pulmonary Clinics.

Presently, our section cares for nearly 13,000 patients annually, treating chronic and acute respiratory illnesses, some of which are noted above. We deeply care for these young patients and their families and provide services at Texas Children's Hospital (Houston), West Campus (Katy), and at our Health Centers in Clear Lake, Sugar Land, Cy-Fair, The Woodlands and Kingwood. In the near future, our services will extend to the new Texas Children's Woodlands Hospital. All of these clinics and centers are staffed by pulmonologists and professionals with special expertise in pediatric respiratory care.


Dr. Michael Gordon, DPM

Dr. Michael Gordon, DPM works in Houston, TX as a Podiatry Specialist.Dr. Gordon has has worked on more claims relating to Foot Infection than other providers in the area. At present, Dr. Gordon has received an average rating of 2.3 from patients and has been reviewed 3 times. They are affiliated with Hca Houston Healthcare Northwest, HCA Houston Healthcare Tomball and HCA Houston Healthcare Kingwood. They are accepting new patients. Dr. Gordon practices at Foot and Ankle Centers of North Houston in Houston, TX and has additional offices in Humble, TX, Livingston, TX and The Woodlands, TX.

  • Aetna
  • Anthem
  • Blue Cross and Blue Shield of Texas
  • Blue Cross Blue Shield
  • Buckeye Community Health Plan
  • CareFirst Blue Cross Blue Shield
  • Cigna
  • First Health
  • Humana
  • Humana Health Plan of Texas
  • Midwest Health Plan
  • MultiPlan
  • UnitedHealthCare

    • * Please verify this information when scheduling an appointment.


    Cindy Gordon

    Dr. Cindy Gordon ICD.D. is a CEO, a thought leader, author, keynote speaker, board director, and advisor to companies and governments striving to modernize their business operations, with advanced AI methods. She is the CEO and Founder of SalesChoice, an AI SaaS company focused





    Comments

    Post a Comment

    Popular posts from this blog

    Roseola vs. measles rash: What is the difference? - Medical News Today

    Image
    Roseola and measles are two different diseases that present with a high fever and a rash. They are both most commonly seen in childhood, although measles can affect people of any age, and roseola in adults is very rare. While both diseases share similarities, there are distinguishing factors, such as how the symptoms present and the disease progression. Read on to find out the difference between roseola and measles rashes. Roseola, also known as roseola infantum, sixth disease, or exanthema subitum, is a viral infection that typically affects children. The human herpesvirus 6 (HHV-6) or human herpesvirus 7 (HHV-7) causes roseola. The disease is spread through tiny respiratory droplets that people either breathe in or pick up from surfaces they touch. This disease usually presents in children between the ages of 6–12 months . Children who have this disease experience a high fever, followed by a pink or red rash. Roseola is a self-limiting viral illness, meaning it will typically go awa...
    Read more

    poliomyelitis treatment

    Image
    poliomyelitis treatment Drug and Device News March 2019 - P&T Community Posted: 04 Mar 2019 10:35 AM PST NEW DRUG APPROVALS Ontruzant, a Herceptin Biosimilar The FDA has approved trastuzumabdttb (Ontruzant, Samsung Bioepis Company, Ltd.) for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Trastuzumabdttb, a HER2/neu receptor antagonist, is the third FDA-approved biosimilar of Herceptin (Genentech). Patients should be selected for therapy based on an FDA-approved companion diagnostic. Trastuzumab-dttb carries a boxed warning about the risks of cardiomyopathy, serious and fatal infusion reactions, embryo-fetal toxicity, and pulmonary toxicity. Ontruzant will be marketed and distributed in the U.S. by Merck. Sources: Samsung Bioepis, January 21, 2019; Ontruzant . prescribing information, January 2019; FDA, January 18, 2019 Vaxelis, a Combination Vaccine T...
    Read more

    Coronavirus fake news echoes century-old polio fears - Newsroom

    Image
    Coronavirus fake news echoes century-old polio fears - Newsroom Coronavirus fake news echoes century-old polio fears - Newsroom Posted: 05 Feb 2020 08:32 AM PST FEBRUARY 6, 2020 Updated 15 hours ago Dr Heather Battles Dr Heather Battles is a lecturer in anthropology at the University of Auckland and researches infectious diseases and epidemics. Show more Ideasroom During the past month, in the confusion and uncertainty over the precise origin of the 2019 novel coronavirus outbreak, many alternate ideas or 'conspiracy theories' have sprung up and spread widely via social media including Twitter and Facebook. I have had a sense of déjà vu as many of these claims have parallels in how people responded to another 'emerging' epidemic disease a century ago: polio. The first example that struck me is the idea (spread by US fake news website Infowars and others) that the roll-out of 5G technology is to blame, wit...
    Read more